received either ‘traditional’ or low-dose ablation. Prior to therapy, patients were advised to eat a diet low in iodine for 1–2 weeks and all doses were administered under conditions of high TSH, predominantly achieved with recombinant TSH. Patients were
Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer
Eugenie S Lim, Shanty G Shah, Mona Waterhouse, Scott Akker, William Drake, Nick Plowman, Daniel M Berney, Polly Richards, Ashok Adams, Ewa Nowosinska, Carmel Brennan, and Maralyn Druce
Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer
Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim, and Erik K Alexander
radioactive iodine (RAI) ( 131 I) ablation, followed by thyroid hormone suppression therapy (6, 7, 8, 9) . Though there may be benefits to this approach, especially for patients with advanced disease, increasing evidence confirms that such a standardized
Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease
Adriano N Cury, Verônica T Meira, Osmar Monte, Marília Marone, Nilza M Scalissi, Cristiane Kochi, Luís E P Calliari, and Carlos A Longui
surgical procedure that can effect complications, depending on the surgeon's experience (1) . Radioactive iodine (RAI) therapy has been used frequently, especially in the USA (7) , as an alternative first-line therapy to surgery and ATDs. The incidence
Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases
Keiko Ohkuwa, Kiminori Sugino, Mitsuji Nagahama, Wataru Kitagawa, Kenichi Matsuzu, Akifumi Suzuki, Chisato Tomoda, Kiyomi Hames, Junko Akaishi, Chie Masaki, and Koichi Ito
patients with DTC and is predominantly observed in the lungs and bone ( 3 , 4 , 5 , 6 ). When treating metastatic tumors of differentiated thyroid carcinoma, a favorable prognosis can be expected after radioactive iodine (RAI) therapy after total
Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy
Guoquan Zhu, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen, and Jiaxin Luo
to that of the wild-type group. One possible reason for this unexpected finding might be that all patients received postsurgical RAI therapy in our study. According to previous research, radioactive iodine (RAI) therapy, as an important adjuvant
Machine learning identifies baseline clinical features that predict early hypothyroidism in patients with Graves’ disease after radioiodine therapy
Lian Duan, Han-Yu Zhang, Min Lv, Han Zhang, Yao Chen, Ting Wang, Yan Li, Yan Wu, Junfeng Li, and Kefeng Li
validation set. RAI, radioiodine therapy; ROC, receiver operator characteristic curve; HT, hypothyroidism; NC, the normal control group; AST, aspartate aminotransferase; TRAb, thyrotropin-receptor antibodies; 24-h RAIU, radioactive iodine uptake at 24 h; TMA
Delayed risk stratification system in pT1aN0/Nx DTC patients treated without radioactive iodine
Danuta Gąsior-Perczak, Iwona Pałyga, Monika Szymonek, Artur Kowalik, Agnieszka Walczyk, Janusz Kopczyński, Katarzyna Lizis-Kolus, Anna Słuszniak, Janusz Słuszniak, Tomasz Łopatyński, Ryszard Mężyk, Stanisław Góźdź, and Aldona Kowalska
many cases, lobectomy (L) is sufficient as surgical treatment and radioactive iodine ( 131 I) therapy is often unnecessary ( 7 ). Much attention has been paid to personalizing the way the disease is monitored; however, research efforts have focused on
Hyperthyroidism in adolescents
Marek Niedziela
.1530/EC-12-0049 ) 40 Kaplowitz PB Jiang J Vaidyanathan P . Radioactive iodine therapy for pediatric Graves’ disease: a single-center experience over a 10-year period . Journal of Pediatric Endocrinology and Metabolism 2020 33 383 – 389 . ( https
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity
Klaudia Zajkowska, Janusz Kopczyński, Stanisław Góźdź, and Aldona Kowalska
inclusion and exclusion criteria has an extremely indolent clinical behaviour, even when treated conservatively with lobectomy and without radioactive iodine therapy. Nevertheless, it cannot be considered as a benign lesion. The risk of adverse outcomes
Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models
Joanna Klubo-Gwiezdzinska, John Costello Jr, Kirk Jensen, Aneeta Patel, Rok Tkavc, Douglas Van Nostrand, Kenneth D Burman, Leonard Wartofsky, and Vasyl Vasko
Introduction Standard treatment of thyroid cancer consists of surgical resection and radioiodine ( 131 I) therapy ( 1 ). Depending on the risk stratification of the individual patient, the primary goal of the application of radioactive iodine
